Clinical Trial Update: ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of ALS20-101, a lentiviral gene therapy for beta-thalassemia, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• ALS20-101 Lentiviral Gene Therapy

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Beta-Thalassemia | Phase 1, Phase 2 | Status: RECRUITING